Adefovir Dipivoxil for the Treatment of Hepatitis B in Human Immunodeficiency Virus Infected Patients With Decompensated Hepatitis B Liver Disease and a Hepatitis B Viral Load of at Least 1.0 X 10(6) (Copies/mL) Despite 52 Weeks of Lamivudine Therapy
Inclusion Criteria
INCLUSION CRITERIA:
Age greater than or equal to 18 years
Infection with HBV with HBV viral load greater than or equal to 1.0 x 10(6) copies/mL by
Roche assay at screen
HIV-infected as documented by ELISA and Western Blot in NIAID clinic (any CD4/HIV viral
load)
Decompensated cirrhosis (Child-Pugh Score greater than or equal to 7: Class B or C
cirrhosis)
Class A with Score of 6 acceptable if secondary to ascites grading and not encephalopathy
or laboratory abnormality (PT, albumin, bilirubin).
Able to return to NIH for study visits
Have a physician(s) outside of NIH who will provide routine, as well as HIV and liver
specific, care.
Receiving lamivudine at a dose of at least 100 mg qd for greater than or equal to one year
prior to enrollment (with no dosing interruptions of greater than 1 month total in the
previous year and no interruption in the 3 months prior to study entry)
Serum creatinine less than 1.5 mg/dL
Serum phosphorus greater than or equal to 2.2 mg/dL (normal range NIH 2.3-4.3 mg/dL)
Neutrophil count greater than or equal to 1000 cells/mm(3)
Platelets greater than or equal to 50,000/mm(3)
Hemoglobin greater than or equal to 8.0 mg/dL
ALT less than or equal to 287 (7 X the NIH upper limit of normal)
Not pregnant or breast-feeding. Pregnancy test must be negative within two weeks prior to
dosing with study medications.
If capable of pregnancy: use of effective contraception during study: effective
contraception methods include abstinence, surgical sterilization of either partner,
barrier methods such as diaphragm, condom, cap or sponge, or use of hormonal contraception
with an anti-HIV regimen that will not alter metabolism of hormonal contraception
Willing and able to provide written informed consent
Because liver disease can result in encephalopathy, willing to designate a person for
durable power of attorney on the NIH form for medical research and medical care purposes
at the NIH Clinical Center
EXCLUSION CRITERIA:
Prior use of ADV (outside of patient receiving adefovir from NIH under emergency use IND)
or prior use of tenofovir, or cidofovir
Active serious systemic infections other than HIV or HBV
Liver disease caused by reasons other than hepatitis B e.g., HCV, HDV, Wilson's,
hemochromatosis, autoimmune hepatitis (ANA greater than or equal to 160) except history of
drug-associated hepatitis with discontinuation of causative agent
History of significant encephalopathy
History of clinically significant pancreatitis
History of untreated varices
New AIDS-defining event other than esophageal candidiasis diagnosed within one month prior
to baseline
Decompensated heart failure
Treatment with immunomodulator drugs (interferons, interleukins, corticosteroids in
greater than physiologic doses) in the 4 weeks prior to baseline. G-CSF and epoietin use
are permitted.
Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG,
clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that
ended more than 12 weeks prior to screen.
Hepatic mass suggestive of hepatocellular carcinoma
Alpha-fetoprotein level greater than or equal to 200ng/mL
Evidence of gastrointestinal malabsorption or chronic nausea or vomiting
Current alcohol or substance abuse that potentially could interfere with patient
compliance
Malignancy other than cutaneous Kaposi's sarcoma, skin cancer treated by resection or
HPV-associated carcinoma in situ or Bowen's disease in the 5 years prior to enrollment
History of clinically significant renal dysfunction within the previous 12 months prior to
baseline
Concomitant therapy with aminoglycosides, amphotericin B, cidofivir, cisplatinum, IV
pentamidine, vancomycin, systemic chemotherapeutic agents, probenecid or other nephrotoxic
agents
Proteinuria (greater than or equal to 3+)
ANA greater than or equal to 3 EU
Positive PCR test for hepatitis C
Antibodies to hepatitis D (delta hepatitis)
Pregnancy or breast-feeding
History of organ or bone marrow transplantation
Any systemic illness that will make it unlikely that the subject will be able to return to
NIH for the required study visits.